IgG2a production) is not correlated with disease state. These data suggest that along the spectrum of murine cutaneous leishmaniasis, IL4 is a reliable indicator of disease, but IFN-y is not prognostic for resistance.
Infection of mice with Leishmania major has been used widely as an experimental model system for the study of human leishmaniasis (46) . The majority of inbred strains of mice develop small lesions that heal (resistant strains), while a few strains develop large lesions and fatal visceralizing infections (susceptible strains). Mice of certain strains, such as A/J, show variability in their susceptibility to infection with L. major, with some mice in the group being cured and others not (intermediate strains), a phenomenon that may reflect a combination of genetic and environmental factors (8) . Most studies on the immune mechanisms responsible for resistance or susceptibility have made use of two inbred strains of mice that are genetically susceptible (BALB/c) and resistant (C57BL/6) to chronic disease. The divergent outcomes following infection with L. major in these mice correlate with the relative abundances of particular lymphokine mRNAs in draining lymph nodes and spleens (10, 11) . Thus, BALB/c nonhealing mice produce interleukin 4 (IL-4) and IL-10 and lower levels of gamma interferon (IFN--y), whereas the reciprocal pattern is found in C57BL/6 healing mice late in infection. On the basis of these and earlier data, it has been suggested that the prognosis of a Leishmania infection can be determined by analyzing the lymphokines produced by Leishmania-specific cells from infected mice and humans (5, 19, 27, 31, 36 kine profiles in BALB/c and C57BL/6 mice have been subjected to intensive investigation, very little is known about lymphokine responses to L. major infections in other strains of mice. This information would show further whether IFN-ao and IL-4 are indeed reliable indicators of cure and progressive disease, respectively. In this study, we showed that for 13 strains of mice that differ in their susceptibility to L. major, only IL-4 levels correlated with disease severity, suggesting that in murine cutaneous leishmaniasis, IL-4 is a reliable indicator of disease, but IFN--y is not prognostic for resistance.
MATERIALS AND METHODS
Mice. AIJ, BALB/c, BALB.G, BALB.K, BALB/c x C57BL/6J (B/c x C57), B10.A(4R), CBA/N, CBA.bg, CB.17, C57BL/6J, C57BL/6bg, C57B10pdWf x DBA/2Wf (Wf/Wf Fl), and NZW mice were bred at The Walter and Eliza Hall Institute of Medical Research under specificpathogen-free conditions and maintained conventionally. All mice used were female, aged 7 to 12 weeks. BALB/c nu/nu (hypothymic) mice were used for in vivo passaging of L. major parasites.
Parasites. Virulent L. major line V121 (9) was cloned from the original LRC-L137 stock obtained from the World Health Organization Reference Centre for Leishmaniasis, Jerusalem, Israel. Amastigotes were harvested from skin lesions of BALB/c nu/nu mice by use of a rapid protocol developed by Glaser et al. (6) . Groups of eight mice were injected with 2 x 106 amastigotes intradermally at the base of the tail. Lesion development was monitored weekly and 3460 MORRIS ET AL. assigned a score from 1 to 4 (where 1 represents a small localized swelling and 4 represents a large disseminating lesion) as detailed previously (20) .
Media and reagents. Cells were cultured in modified DME (14) supplemented with 216 mg of L-glutamine per liter, 5 x 10-M 2-mercaptoethanol, and 5% fetal calf serum (Flow Laboratories, North Ryde, Australia) (DME-5% FCS) in a humidified atmosphere of 5% CO2 in air. The culture supernatant from cells transfected with mouse IL-4 cDNA (13) (a gift from F. Melchers, Basel Institute for Immunology, Basel, Switzerland) was used as a source of recombinant IL-4. Recombinant IFN--y was purchased from Genentech Inc., San Francisco, Calif. Soluble leishmanial antigen (SLA) was prepared with V121 promastigotes grown in Schneider's drosophila medium (GIBCO BRL Life Technologies, Inc., Penrose, Auckland, New Zealand) containing 10% fetal calf serum as described previously (25) .
RNA preparation. The draining lymph nodes (inguinal and lower periaortic) from at least three mice per group were pooled and homogenized in 6 M guanidine isothiocyanate-25 mM citrate-0.5% sodium lauroylsarcosinate-50 mM 2-mercaptoethanol by use of a Dounce homogenizer. RNA was purified from the homogenate as described previously (18) .
Si nuclease protection analysis. S1 nuclease protection experiments were performed essentially as described by Berk and Sharp (4) with 65 ,ug of total RNA or yeast tRNA (Boehringer GmbH, Mannheim, Germany) and 32P-endlabeled probes for IFN-y (44) or glyceraldehyde-phosphate dehydrogenase (GAP-DH) (30) . Before electrophoresis, the samples were denatured in 200 ,u of 0.3 M NaOH-1 mM EDTA at 65°C for 10 min and neutralized by the addition of 20 RI of 3 M HCl-10 mM Tris (pH 7.6)-i mM EDTA. Five micrograms of carrier tRNA was added to the samples, and nucleic acids were precipitated with ethanol. Protected fragments were separated on a 5% polyacrylamide sequencing gel and quantitated on a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.) by use of ImageQuant software (Molecular Dynamics). Relative signal intensities were calculated after background subtraction and normalization of the total mRNA content of each sample on the basis of the GAP-DH mRNA content. The amount of IFN-y mRNA detected in RNA from infected BALB/c mice was arbitrarily set at 10 U.
PCR analysis. Synthesis of cDNA, the polymerase chain reaction (PCR), and PCR oligonucleotide primers for IL-4 and IFN-y have been described (18, 43) . PCR oligonucleotide primers for 0-actin were as follows: 5' primer, GACAT GGAGAAGATCTGGCA; 3' primer, GGTCTITACGGATG TCAACG. All primer pairs were included in each reaction. Quantitation of relative levels of mRNA was performed by an adaptation of the procedures originally described by with modifications (21) . In brief, six fourfold serial dilutions of each cDNA sample were subjected to PCR amplification; serial dilutions of cloned cDNAs starting at an input dose of 10-15 g were used as a standard for the quantitation of sample cDNAs. The PCR products were analyzed by Southern blotting as described previously (18, 43) , and the amount of a cDNA-specific product generated was determined by use of ImageQuant software on a PhosphorImager. Plots of the logarithm of PCR product yield versus the logarithm of cDNA input for each sample were compared with a standard curve generated by use of cloned cDNA to quantitate the levels of specific cDNAs in the starting samples. Lymphokine transcript levels were determined after normalization to the level of the constitutively expressed ,B-actin transcript to compensate for intersample differences in RNA integrity, cDNA synthesis, or PCR efficiency. Reverse were harvested and pooled. Single-cell suspensions were prepared by forcing tissues through a fine wire mesh and washing them twice by centrifugation. Cells (2 x 106) were cultured in 1 ml of DME-5% FCS in 48-well plates (Costar, Cambridge, Mass.) in the presence or absence of antigen (25 p,g of SLA per ml). Supernatants were harvested 24 h later for lymphokine analysis. Lymphokine assays. IL-4 and IFN--y were assayed with the specific lymphokine-responsive cell lines CT.4S and WEHI-279 as described previously (25) . Tissue culture supernatants containing anti-IL-4 monoclonal antibody llBl (28) or neutralizing anti-IFN--y monoclonal antibody R4-6A2 (ATCC HB170) (40) were used to confirm the specificity of these assays.
Antibody titers. Pooled sera from two mice per group (or individual mice as indicated) were assayed for anti-L. major immunoglobulin Gl (IgGl) and IgG2a antibodies by an isotype-specific enzyme-linked immunosorbent assay (ELISA) (22) . Round-bottom 96-well polyvinyl chloride plates (Dynatech, Chantilly, Va.) were coated with 50 p,g of SLA per ml, and the remaining reactive sites were blocked with phosphate-buffered saline containing 5% skim milk plus 0.05% Tween 20. Serially diluted sera were added at room temperature, and horseradish peroxidase-conjugated goat anti-mouse IgGl or IgG2a (Southern Biotechnology Associates, Birmingham, Ala.) was added 1 h later. Bound antibodies were detected with ABTS [2,2'-azino-di-(3-ethylbenzothiazoline-6 sulfonic acid)] (Pierce, Rockford, Ill.). Titers were determined from the linear portion of parallel doseresponse curves and were the reciprocal of the dilution at which samples showed an optical density reading of 0.7.
RESULTS
Infection of mice with L. maior. Mice of 43 different inbred, congenic, and hybrid strains were injected intradermally at the base of the tail with L. major V121 amastigotes, and lesion development was monitored for 9 weeks. The majority of mice developed lesions that resolved at different times over the 9 weeks, while mice from a few strains failed to heal their lesions. Thirteen different strains that covered this spectrum of susceptibility were selected for further analysis. BALB/c, BALB.G, CB.17, and NZW were all highly susceptible to infection, and all mice in each group developed large lesions by 9 weeks postinfection. Among the resistant strains, CBA/N and CBA.bg were the most resistant, showing little or no effect at the injection site, whereas C57BL/6 and C57BL/6bg developed small lesions (mean lesion score, 1) that healed over a period of 6 to 8 weeks. Five strains [A/J, BALB.K, B/c x C57, BlO.A(4R), and Wf/Wf F1] showed intermediate resistance; the majority of mice showed lesion cure over 6 to 8 weeks, but a few (one to four of eight mice) failed to heal their lesions over a 3-month period. This variation in lesion score among strains showing intermediate resistance was noted in three separate experiments. The mean lesion scores in mice of these strains were higher at the peak of the acute phase (3 to 6 weeks postinfection) than were those in mice of resistant strains (data not shown). Figure 2 shows that there was a ermediate resistance, these broad range of IL-4 mRNA levels among the strains anaf ongoing disease, as evilyzed. The PCR used was shown to be linear over a up to 7 months later. > 1,000-fold range of dilutions and was able to detect < 10-17 ntermediate strains of mice g of cloned IL-4 cDNA (Fig. 3) . The fact that plots of the ction, since this time point logarithm of PCR product yield versus the logarithm of stages of infection; i.e., When IFN--y and IL-4 mRNA levels were plotted against the lesion scores of the mice from which the mRNAs were derived, less variation was observed in the levels of IFN-y than in the levels of IL-4 for the different strains of mice (note the ordinate scales in Fig. 4 ). This result was not due to the different methods used, since similar results were obtained when IFN--y levels were quantitated by PCR analysis instead of by Si nuclease analysis (data not shown). This analysis showed a correlation between IL-4 mRNA levels and disease and no link between IFN--y mRNA expression and resistance to disease.
Secreted lymphokine titers. For assessment of whether in vivo lymphokine mRNA levels reflected the Leishmaniaspecific immune response, lymph node cells from mice infected for 9 weeks were stimulated in vitro for 24 h with an L. major antigen (SLA) and assayed for the secretion of lymphokines. IL-4 could not be detected in cultures stimulated with SLA for any of the infected mice (data not shown). IFN-,y titers were four-to fivefold higher in cultures from C57BL/6 mice than in those from BALB/c mice (Fig.  4c) . Except for BALB.G mice, which secreted the lowest titers of IFN--y, titers for all mice lay within a 10-fold range between BALB/c and C57BL/6bg. While susceptible mice secreted some of the lowest titers of IFN--y, cells from some resistant and intermediate strains of mice that showed lesion cure (e.g., CBA.bg, Wf/Wf Fl, and B/c x C57) secreted similarly low titers. An analysis of mice of intermediate strains, some of which did not show lesion cure by 9 weeks postinfection, showed that the levels of IFN-y secretion depended on the genotype of the mouse and not on the presence or absence of lesions. Thus, cells from mice with lesion scores higher than 3 secreted the same amount of IFN--y as cells from mice that were of the same strain and that were from the same box but that did not show lesion cure (Fig. 4c) . Therefore, there was no correlation between lesion scores and Leishmania-specific IFN--y secretion levels among the strains of mice analyzed.
Serum antibody titers. Since antibody levels in serum may be more stable over time than cytokine levels, Leishmaniaspecific antibodies were quantitated. Mice from all strains had elevated titers ofLeishmania-specific IgGl and IgG2a at 9 weeks postinfection, compared with uninfected mice, in which specific antibodies were not detectable (data not shown). However, IgGl titers were up to 50-fold higher in susceptible strains of mice than in resistant and intermediate strains (Fig. 4d) . For three of the intermediate strains, BALB.K, BlO.A(4R), and Wf/Wf Fl, IgGl titers were 3-to 10-fold higher in mice with lesions than in mice that were of the same strain but that did not show lesion cure. This dichotomy was less marked for A/J mice: both cured mice and mice with lesions had high levels of specific IgGl. Nevertheless, there was a correlation between lesion scores and IgGl titers when all strains of mice were compared (Fig.  4d) .
While BALB/c mice showed fivefold-higher levels of IgG2a than C57BL/6 mice, there was no correlation between lesion scores and IgG2a titers for the 13 were calculated from the S1 nuclease protection (Fig. 1 ) and quantitative PCR (Fig. 2) analyses, respectively. IL-4 mRNA data for mice of strains CBA.bg and B1O.A(4R) were not included because of the low levels of actin control mRNA obtained (Fig. 2) (10, 37) . Our studies show that the differences observed between these two strains represent opposite ends of the range of responses seen for a group of 13 mouse strains. These 13 strains were selected because they covered the full spectrum of disease caused by L. major and included highly resistant, intermediately resistant, and highly susceptible mice. H-2 congenic mice and bg (beige) mutant mice, which are deficient in natural killer cells (the only other non-T-cell source of IFN-,y in vivo [7] ), were also included. Differences in the H-2 and bg mutations, however, were found not to influence significantly the Leishmania-induced lymphokine profiles. All mice were analyzed at 9 weeks postinfection. By this time, differences in the severity of disease (lesion score) were obvious between and within strains. Sampling of the different strains at 9 weeks therefore represented a crosssection of murine cutaneous leishmaniasis, similar to the study of one strain at different times during an infection (25) . In highly resistant mice, e.g., CBA/N, the low levels of lymphokine mRNA may be due to the small numbers of parasites as a result of an effective cell-mediated response. However, since parasites persist in all strains of mice following healing of lesions (1, 15, 26) , residual parasites would provide for continuous stimulation of a specific immune response. The in vitro restimulation of antigen-specific cells was an attempt to compensate for the presumably lower antigen-driven T-cell stimulation in vivo in these mice. In agreement with the mRNA data, the levels of IFN--y secreted in vitro did not correlate with lesion score either between strains or within a given strain. In contrast, at 9 weeks postinfection, a strong correlation between IL-4 expression and disease was maintained for all strains studied. Titers of Leishmania-specific IgGl correlated with lesion score, consistent with the role of IL-4 as a switch factor for IgGl (39) , whereas there was no correlation between IgG2a titers (IgG2a production is promoted by IFN--y [39] ) and lesion score.
Studies in vivo and in vitro have demonstrated a role for IFN-y in resistance to an L. major infection (3, 10, 36, 41) , although other lymphokines, such as tumor necrosis factor alpha (TNF-a), have also been implicated (42) . Reduced levels of TNF-a. due to a polymorphism in the TNF-ao locus of NZW mice (12) may account for the susceptibility of these mice to an L. major infection. Nevertheless, our finding that susceptible mice, including BALB/c mice, and mice of intermediate susceptibility with ongoing disease expressed IFN--y during a Leishmania infection suggests that other factors, possibly IL-4, override the protective effects of IFN--y. A causal relationship between the effects of IL-4 and susceptibility to infection is suggested by the finding that the inhibition of IL-4 in vivo by monoclonal antibody treatment resulted in the protection of BALB/c mice (35) . The association of IL-4 with disease is further supported by earlier results showing that IL-4 was expressed in resistant C57BL/6 mice early in infection, when these mice had lesions, but that IL-4 expression declined as their lesions healed (23, 25) . Furthermore, induction of protection in BALB/c mice by a variety of regimens was associated with a decrease in the precursor frequency of IL-4-secreting cells, while the precursor frequency of cells secreting IFN-y remained unchanged, indicating that the levels of IL-4 were correlated with the outcome of the infection (24) . The mechanism of action of IL-4 in a Leishmania infection is not known, although some evidence suggests that IL-4 can inhibit macrophage activation, which could result in uncontrolled parasite expansion (16, 17, 38) . Therefore, in contrast to the current hypothesis, which proposes that the outcome of a Leishmania infection is dependent on the preferential activation of T cells producing either IFN--y (Thi cells) or IL-4 (Th2 cells) (10, 37) , we propose that IFN-y is produced by all mice in response to an infection and that it is the dominant effect of IL-4 and/or other concomitantly expressed lymphokines, e.g., IL-10 (11) or transforming growth factor beta (2) , that determines the severity of disease.
The spectrum of disease seen for mice infected with L. major is similar to that observed for humans infected with different Leishmania species. Although the majority of humans infected with parasites causing cutaneous disease show lesion cure, a few develop severe disease. The study presented here was designed as a model for the situation with leishmaniasis patients in which the time of infection and the genetic susceptibility of the host cannot be examined, but the disease severity can be assessed. Interestingly, no correlation was seen between IFN--y secretion by peripheral blood lymphocytes in response to Leishmania antigens in vitro and disease severity in patients with localized lesions (29, 31) . These data, like the results presented here, suggest that measuring the level of IFN--y secreted in response to parasite antigens is not useful in the prognosis of cutaneous leishmaniasis. It may be interesting, therefore, to examine the levels of IL-4 in humans to assess their correlation with the severity of human disease, as suggested by our data obtained with the murine system.
